CORRECTION
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus
FOLFIRI±bevacizumab in metastatic colorectal cancer
Vera Gorbunova
1, J. Thaddeus Beck
2, Ralf-Dieter Hofheinz
3, Pilar Garcia-Alfonso
4, Marina Nechaeva
5, Antonio Cubillo Gracian
6, Laszlo Mangel
7, Elena Elez Fernandez
8, Dustin A. Deming
9, Ramesh K. Ramanathan
10, Alison H. Torres
11, Danielle Sullivan
11, Yan Luo
11and Jordan D. Berlin
12British Journal of Cancer (2019) 121:429–430; https://doi.org/10.1038/s41416-019-0528-0
Correction to : British Journal of Cancer (2019) 120 , 183 – 189;
https://doi.org/10.1038/s41416-018-0343-z; published online 11 December 2018
The original version of this article contained an error in Fig. 1a.
The number of patients at risk listed in the Veliparib arm of Fig. 1a should have read “ 65 ” instead of “ 35 ” . The correct fi gure is below.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visithttp://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2019
www.nature.com/bjc
Published online: 26 July 2019
1N.N. Blokhin Russian Cancer Research Center, Moscow, Russia;2Highlands Oncology, Rogers/Fayetteville, AR, USA; 3Interdisciplinary Tumor Center, University Hospital Mannheim, University of Heidelberg, Heidelberg, Germany;4Hospital General Universitario Gregorio Marañón, Madrid, Spain;5Arkhangelsk Clinical Oncology Center, Arkhangelsk, Russia;6Centro Integral Oncológico Clara Campal Hospital Universitario Madrid Sanchinarro, Madrid, Spain, and Departamento de Ciencias Médicas Clínicas, Universidad CEU San Pablo, Madrid, Spain;7Pecsi Tudomanyegyetem Klinikai Kozpont, Onkoterapias Intezet, Pécs, Hungary;8Vall d’Hebron University Hospital, Barcelona, Spain;9University of Wisconsin, Madison, WI, USA;10Mayo Clinic, Scottsdale, AZ, USA;11AbbVie Inc., North Chicago, IL, USA and12Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
Correspondence: Jordan D. Berlin ([email protected])
©The Author(s) 2019 Published by Springer Nature on behalf of Cancer Research UK
1.0 0.9 0.8 0.7 0.6 0.5 0.4
Probability of overall survival
0.3 0.2 0.1 0.0
0 2
65 VEL
PBO 65 64 64 62 59 56 53 50 48 45 43 39 28 12 4 2
61 60 55 51 47 46 43 39 38 32 25 19 9 3 0
No. at risk
VEL+F+/–Bev
VEL 25 months (95% CI: 20–) PBO 27 months (95% CI: 22–) PBO+F+/–Bev Median OS
Months since randomisation
4 6 8 10 12 14 16 18 20 22 24 26 28 30
1.0
a
b
0.9 0.8 0.7 0.6 0.5 0.4
Probability of progression-free survival
0.3 0.2 0.1 0.0
0 2
65 VEL
PBO 65 58 51 44 35 29 23 19 12 10 6 4 2 0
57 51 42 31 27 22 16 14 9 8 7 5 1 0
No. at risk
VEL+F+/–Bev
VEL 12 months (95% CI: 10–15) PBO 11 months (95% CI: 8–14)
PBO+F+/–Bev Median PFS
Months since randomisation
4 6 8 10 12 14 16 18 20 22 24 26 28
Fig. 1 a
Progression-free survival at
final analysis and
boverall survival at
final analysis. CI con
fidence interval, PBO placebo
+FOLFIRI ± bevacizumab, VEL veliparib
+FOLFIRI ± bevacizumab
Correction: A phase 2 randomised study of veliparib plus. . . V Gorbunova et al.
430
1234567890();,:
